Summary by Moomoo AI
Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Stock Market under the trading symbol VVOS, has filed a Current Report on Form 8-K with the SEC on June 25, 2024. The report addresses the company's non-compliance with Nasdaq's Listing Rule 5550(b)(1) regarding the minimum stockholders' equity of $2.5 million as of March 31, 2024. Following a $7.5 million private placement completed on June 10, 2024, Vivos Therapeutics believes it now meets the equity requirement. A hearing with a Nasdaq Hearings Panel is scheduled for June 27, 2024, where the company will present its case for continued listing on Nasdaq. The decision from the Panel is expected within 30 days of the hearing. The company acknowledges the risk of being unable to raise sufficient capital to maintain compliance with the Equity Requirement, which could lead to delisting from Nasdaq and have a material adverse effect on the company's operations and stock price.
